Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(2): 277-286
ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. doi: 10.12290/xhyxzz.2021-0180
Citation: ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. doi: 10.12290/xhyxzz.2021-0180
shu

Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome

doi: 10.12290/xhyxzz.2021-0180
  • 1.

    Department of Pharmacy, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Bioactive Substrate and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

  • 3.

    Department of Medical Records, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 4.

    Collaborating Center for the WHO Family of International Classifications in China, Beijing 100730, China

  • 5.

    Department of Nephrology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 6.

    Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

CAMS Innovation Fund for Medical Sciences 2016-I2M-4-001

the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2017PT32020

the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT32001

More Information
  • Corresponding author: YUAN Tao, E-mail: t75y@sina.com
  • Received Date: 2021-02-07
  • Accepted Date: 2021-03-29
  • Publish Date: 2022-03-30
    Abstract
  •   Objective  To analyze the clinical characteristics and medical treatment of patients with Gitelman syndrome(GS) for further improvement.  Methods  A retrospective study was conducted on patients with GS hospitalized in Peking Union Medical College Hospital from January, 2008 to December, 2019. Their clinical manifestations, laboratory examinations, pathological features, and drug treatments were summarized. In addition, according to whether spironolactone is used or not, these patients were divided into a simple potassium supplementation group and a spironolactone-combined group. The effect of treatment between the two groups were compared.  Results  The male to female ratio of 50 patients was 1.5∶1(male: 30, female: 20), and the age at first diagnosis was (30.78±13.99) years old. Among the 50 patients, the most common clinical manifestation was fatigue (54.0%, 27/50), and other clinical manifestations included limb weakness (40.0%, 20/50), limb numbness (26.0%, 13/50), flaccid paralysis (26.0%, 13/50), palpitation (16.0%, 8/50), and nocturia (14.0%, 7/50). At admission, they had serum potassium (2.55±0.45)mmol/L, serum magnesium (0.64± 0.20)mmol/L, 24 h urine potassium (92.25±41.33)mmol, 24 h urine magnesium (3.75±2.14)mmol, and 24 h urine calcium 0.68(0.38, 1.32)mmol. The blood gas analysis Results suggested that most patients had metabolic alkalosis. Seven patients (14.0%, 7/50) underwent renal biopsy, showing 1 case of glomerular mesangial hyperplasia, 5 cases of obvious hyperplasia of juxtaglomerular apparatus, and 1 case of no obvious hyperplasia of juxtaglomerular apparatus. All the 50 patients received oral potassium supplementation of (1.62±1.25)mmol/(kg·d). 46 patients (92.0%, 46/50) were treated with potassium chloride sustained-release tablets (1.5-12 g/d) for potassium supplementation, while 19 patients (38.0%, 19/50) received regimens containing oral solution of 20% potassium citrate (40-200 mL/d, 2-4 times/d). In addition, potassium magnesium aspartate (2-15 tablets/d) was used in 37 patients (74.0%, 37/50), and spironolactone (20-240 mg/d) in 32 patients (64.0%, 32/50). For 2 patients (4.0%, 2/50), calcium and magnesium tablets (3 tablets/d) were applied. To be noted, the increase of serum potassium after treatment in the spironolactone-combined group was significantly higher than that in the simple potassium supplement group [(1.07±0.61)mmol/L vs. (0.73±0.59)mmol/L, P < 0.05]. At discharge, the serum potassium was (3.49±0.44)mmol/L, and the serum magnesium was (0.67±0.16)mmol/L in 50 patients.  Conclusions  GS occurs more often in adolescents and adults, but is also witnessed in children. It is characterized most commonly by fatigue, and accompanied by other clinical manifestations like hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis, and renin-angiotensin-aldosterone system activation. Symptomatic treatment is its main therapy, and the combination of spironolactone can improve the effect of potassium supplementation. Patients with GS have favorable prognosis.
    • FullText(HTML)
  • loading
    • References(33)
  • [1] Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia[J]. Trans Assoc Am Physicians, 1966, 79: 221-235.
    [2] Fujimura J, Nozu K, Yamamura T, et al. Clinical and Genetic Characteristics in Patients With Gitelman Syndrome[J]. Kidney Int Rep, 2019, 4: 119-125. doi:  10.1016/j.ekir.2018.09.015
    [3] Chinen T, Saeki E, Mori T, et al. A case of Gitelman syndrome: our experience with a patient treated in clinical practice on a local island[J]. J Rural Med, 2019, 14: 258-262. doi:  10.2185/jrm.3014
    [4] Kavak Sinanoǧlu G, Aydn M. A Case of Gitelman Syndrome Diagnosed with Anorexia Nervosa in a Psychiatry Clinic[J]. Turk Psikiyatri Derg, 2020, 31: 69-73.
    [5] Uzunlulu M, Dumanoglu B. Gitelman Syndrome Presenting with Hypomagnesemia, Hypokalemia and Hypocalciuria: A Case Report[J]. Medeni Med J, 2019, 34: 314-317.
    [6] 何俊俊, 陈月平, 赵咏莉, 等. Gitelman综合征1例报道并文献复习[J]. 皖南医学院学报, 2020, 39: 610-612. doi:  10.3969/j.issn.1002-0217.2020.06.029

    He JJ, Chen YP, Zhao YL, et al. Gitelman syndrome: Report of 1 case with literature review[J]. Wannan Yixueyuan Xuebao, 2020, 39: 610-612. doi:  10.3969/j.issn.1002-0217.2020.06.029
    [7] 马骞, 武锦琳, 车凌仪, 等. 一例Gitelman综合征家系的基因变异分析[J]. 中华医学遗传学杂志, 2020, 37: 1368-1370. doi:  10.3760/cma.j.cn511374-20200520-00361

    Ma Q, Wu JL, Che LY, et al. Identification of pathological variants of SLC12A3 gene in a pedigree affected with Gitelman syndrome[J]. Zhonghua Yixue Yichuanxue Zazhi, 2020, 37: 1368-1370. doi:  10.3760/cma.j.cn511374-20200520-00361
    [8] 郑晓玲, 唐莹, 鲁一兵, 等. Gitelman综合征1例及文献复习[J]. 临床检验杂志, 2019, 37: 714-716. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJY201909020.htm

    Zheng XL, Tang Y, Lu YB, et al. A case of Gitelman syndrome and literature review[J]. Linchuang Jianyan Zazhi, 2019, 37: 714-716. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJY201909020.htm
    [9] 中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, 等. Gitelman综合征诊疗中国专家共识(2021版)[J]. 协和医学杂志, 2021, 12: 902-912. doi:  10.12290/xhyxzz.2021-0555

    Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, et al. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Xiehe Yixue Zazhi, 2021, 12: 902-912. doi:  10.12290/xhyxzz.2021-0555
    [10] Seyberth HW, Weber S, Kömhoff M. Bartter's and Gitelman's syndrome[J]. Curr Opin Pediatr, 2017, 29: 179-186. doi:  10.1097/MOP.0000000000000447
    [11] Fulchiero R, Seo-Mayer P. Bartter Syndrome and Gitelman Syndrome[J]. Pediatr Clin North Am, 2019, 66: 121-134. doi:  10.1016/j.pcl.2018.08.010
    [12] 唐黎之, 童南伟. 成人Gitelman综合征的诊治[J]. 华西医学, 2018, 33: 605-610. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX201805021.htm

    Tang LZ, Tong NW. The diagnosis and treatment of Gitelman syndrome in adults[J]. Huaxi Yixue, 2018, 33: 605-610. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX201805021.htm
    [13] Nozu K, Nozu Y, Nakanishi K, et al. Cryptic exon activation in SLC12A3 in Gitelman syndrome[J]. J Hum Genet, 2017, 62: 335-337. doi:  10.1038/jhg.2016.129
    [14] Jiang L, Chen C, Yuan T, et al. Clinical severity of Gitelman syndrome determined by serum magnesium[J]. Am J Nephrol, 2014, 39: 357-366. doi:  10.1159/000360773
    [15] Yuan T, Jiang L, Chen C, et al. Glucose tolerance and insulin responsiveness in Gitelman syndrome patients[J]. Endocr Connect, 2017, 6: 243-252. doi:  10.1530/EC-17-0014
    [16] 彭晓艳, 蒋兰萍, 袁涛, 等. 氯离子清除试验在Gitelman综合征鉴别诊断中的应用[J]. 中国医学科学院学报, 2016, 38: 275-282. doi:  10.3881/j.issn.1000-503X.2016.03.006

    Peng XY, Jiang LP, Yuan T, et al. Value of Chloride Clearance Test in Differential Diagnosis of Gitelman Syndrome[J]. Zhongguo Yixue Kexueyuan Xuebao, 2016, 38: 275-282. doi:  10.3881/j.issn.1000-503X.2016.03.006
    [17] 马骏, 任红, 谢静远, 等. Gitelman综合征47例临床特征分析[J]. 中国实用内科杂志, 2014: 273-276, 280. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201403018.htm

    Ma J, Ren H, Xie JY, et al. Clnical analysis of 47 cases of Gitelman syndrome[J]. Zhongguo Shiyong Neike Zazhi, 2014: 273-276, 280. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201403018.htm
    [18] Tammaro F, Bettinelli A, Cattarelli D, et al. Early appearance of hypokalemia in Gitelman syndrome[J]. Pediatr Nephrol, 2010, 25: 2179-2182. doi:  10.1007/s00467-010-1575-1
    [19] Urwin S, Willows J, Sayer JA. The challenges of diagnosis and management of Gitelman syndrome[J]. Clin Endocrinol (Oxf), 2020, 92: 3-10. doi:  10.1111/cen.14104
    [20] Nakhoul F, Nakhoul N, Dorman E, et al. Gitelman's syndrome: a pathophysiological and clinical update[J]. Endocrine, 2012, 41: 53-57. doi:  10.1007/s12020-011-9556-0
    [21] Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2017, 91: 24-33. doi:  10.1016/j.kint.2016.09.046
    [22] Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension[J]. J Hypertens, 2013, 31: 3-15. doi:  10.1097/HJH.0b013e3283599b6a
    [23] Blanchard A, Vargas-Poussou R, Vallet M, et al. Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome[J]. J Am Soc Nephrol, 2015, 26: 468-475. doi:  10.1681/ASN.2014030293
    [24] 崔云英, 李明, 王芬, 等. 氨苯蝶啶或吲哚美辛在Gitelman综合征患者中的疗效分析[J]. 基础医学与临床, 2019, 39: 1603-1606. doi:  10.3969/j.issn.1001-6325.2019.11.017

    Cui YY, Li M, Wang F, et al. Therapeutic efficacy of triamterene or indomethacin in patients with Gitelman syndrome[J]. Jichu Yixue Yu Linchuang, 2019, 39: 1603-1606. doi:  10.3969/j.issn.1001-6325.2019.11.017
    [25] Hené RJ, Koomans HA, Dorhout Mees EJ, et al. Correction of hypokalemia in Bartter's syndrome by enalapril[J]. Am J Kidney Dis, 1987, 9: 200-205. doi:  10.1016/S0272-6386(87)80055-0
    [26] Morales JM, Ruilope LM, Praga M, et al. Long-term enalapril therapy in Bartter's syndrome[J]. Nephron, 1988, 48: 327. doi:  10.1159/000184954
    [27] Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits[J]. Expert Rev Clin Pharmacol, 2015, 8: 221-231. doi:  10.1586/17512433.2015.1005074
    [28] Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone[J]. Int J Cardiol, 2015, 200: 25-29. doi:  10.1016/j.ijcard.2015.05.127
    [29] Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review[J]. Expert Opin Drug Saf, 2012, 11: 779-795. doi:  10.1517/14740338.2012.712109
    [30] Cho YJ, Park GT, Cho YJ, et al. Renal potassium wasting and hypocalciuria ameliorated with magnesium repletion in Gitelman's syndrome[J]. J Korean Med Sci, 1997, 12: 157-159. doi:  10.3346/jkms.1997.12.2.157
    [31] Robinson CM, Karet Frankl FE. Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes[J]. Nephrol Dial Transplant, 2017, 32: 508-512.
    [32] Rodríguez-Soriano J. Bartter and related syndromes: the puzzle is almost solved[J]. Pediatr Nephrol, 1998, 12: 315-327. doi:  10.1007/s004670050461
    [33] Gröber U. Magnesium and Drugs[J]. Int J Mol Sci, 2019, 20: 2094. doi:  10.3390/ijms20092094
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1152) PDF downloads(65) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return